**Core Concept**
The **B-Thalassemia trait** is a genetic disorder characterized by a mutation in the **HBB** gene, leading to reduced production of the **beta-globin** chain of hemoglobin. This results in a mild anemia with distinct laboratory findings. The underlying principle being tested is the pathophysiology of **thalassemia** and its effects on hematological parameters.

**Why the Correct Answer is Right**
In **B-Thalassemia trait**, there is a compensatory increase in the production of **delta-globin** and **gamma-globin** chains, leading to an elevation of **HbA2** (alpha2delta2) and **HbF** (fetal hemoglobin, alpha2gamma2). However, the most specific and commonly elevated parameter in **B-Thalassemia trait** is **HbA2**.

**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because while **HbF** can be elevated, it's not as specific or consistently elevated as **HbA2** in **B-Thalassemia trait**.
**Option B:** Incorrect as it is not directly related to the compensation mechanism in **B-Thalassemia trait**.
**Option D:** Incorrect because it does not accurately reflect the primary hematologic alteration in **B-Thalassemia trait**.

**Clinical Pearl / High-Yield Fact**
A key point to remember is that **HbA2** levels are typically elevated above 3.5% in **B-Thalassemia trait**, which helps differentiate it from other causes of microcytic anemia.

**Correct Answer:** D. HbA2